Global Finance News
26 Jun 2026, 15:27
AstraZeneca (NASDAQ: AZN) gained 1.5% on Friday after Jefferies reiterated its Buy rating, reinforcing confidence in the pharmaceutical giant's long-term growth prospects.
The reaffirmed bullish view reflects optimism surrounding AstraZeneca's diversified portfolio of blockbuster medicines, expanding oncology and rare disease franchises, and a robust late-stage pipeline. Jefferies believes the company remains well positioned to deliver sustainable earnings growth through continued product launches and global demand for its innovative therapies.
The positive analyst commentary helped support investor sentiment, with shares moving higher as the market continued to favor defensive healthcare names alongside companies offering strong long-term earnings visibility.
The reaffirmed bullish view reflects optimism surrounding AstraZeneca's diversified portfolio of blockbuster medicines, expanding oncology and rare disease franchises, and a robust late-stage pipeline. Jefferies believes the company remains well positioned to deliver sustainable earnings growth through continued product launches and global demand for its innovative therapies.
The positive analyst commentary helped support investor sentiment, with shares moving higher as the market continued to favor defensive healthcare names alongside companies offering strong long-term earnings visibility.